Clinical operations

Who can make 14 study visits? Mevidalen and site feasibility

Lilly stopped the Alzheimer’s program after the Phase 2 results fell short of its threshold to continue.

By Lampgen Clinical Research

Study coordinator and older man reviewing a calendar under the headline Who can make 14 visits?
AI-generated editorial illustration.
Study partner requiredUp to 14 visits
Approximately 26 weeks

What the source reported

Lilly’s Phase 2 mevidalen study in mild to moderate Alzheimer’s dementia called for a reliable study partner. Lilly’s participant guide described approximately 26 weeks of participation and up to 14 visits. For a site, that fits into a schedule of assessments. For a household, it can mean arranging transportation, taking time off work and coordinating two people’s calendars for half a year.

Who can participate?

Lilly stopped the Alzheimer’s program after the Phase 2 results fell short of its threshold to continue. The visit schedule raises a separate question for trial teams about who has a practical opportunity to contribute to the evidence.

A site feasibility scenario

At Lampgen, we’d put that question to an oncology CRA candidate as a site scenario. A coordinator expects to enroll ten patients. Several otherwise eligible families say they can make the first visit but are unsure about the rest. What would you bring back to the sponsor before accepting that forecast?

We’d listen for specifics. Which visit creates the difficulty? How long will the patient be at the site? Which assessments must happen in person? What travel or scheduling support can the site actually offer under the protocol?

What this means for trial teams

An experienced CRA can give the sponsor something more actionable than a lower enrollment estimate. They can identify the visit that families are struggling to make while the team still has time to address it.

Sources

  1. Lilly study overview
  2. ClinicalTrials.gov record
  3. Reporting on Lilly’s decision

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?